KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Liabilities and Shareholders Equity (2016 - 2025)

Arbutus Biopharma's Liabilities and Shareholders Equity history spans 15 years, with the latest figure at $97.7 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 30.43% year-over-year to $97.7 million; the TTM value through Sep 2025 reached $449.7 million, down 24.44%, while the annual FY2024 figure was $131.7 million, 8.79% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $97.7 million at Arbutus Biopharma, down from $103.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $215.8 million in Q2 2022 and bottomed at $97.7 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $150.3 million (2024), against an average of $157.2 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 59.43% in 2022 before it tumbled 35.48% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $204.5 million in 2021, then decreased by 4.43% to $195.4 million in 2022, then dropped by 26.11% to $144.4 million in 2023, then fell by 8.79% to $131.7 million in 2024, then dropped by 25.81% to $97.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Liabilities and Shareholders Equity are $97.7 million (Q3 2025), $103.3 million (Q2 2025), and $117.0 million (Q1 2025).